STOCK TITAN

HAEMONETICS (HAE) SEC Filings, Jul 28, 2026

HAE NYSE

Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.

The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.

Rhea-AI Summary

Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Martin D. Madaus received a grant of 2,538 restricted stock units under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on July 24, 2026. The RSUs vest 100% on the first anniversary of the grant date, with each unit delivering one share of common stock and 2,538 shares reported as directly owned after the award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corporation director Ellen M. Zane received a grant of 2,538 restricted stock units under the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and her direct common stock holdings total 21,911 shares after the award.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

Pomeroy Claire reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Claire Pomeroy reported a grant of 2,538 restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU delivering one share of common stock upon vesting. After this award, her direct holdings total 19,410 shares of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
Rhea-AI Summary

KROLL MARK W reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Mark W. Kroll reported an equity award of 2,538 restricted stock units (RSUs) granted under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one (1) share of common stock when vested. Following this award, his reported direct holdings are 27,295 common shares, including these RSUs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

Haemonetics Corp director Lloyd Emerson Johnson reported an equity compensation award of 2,538 shares of common stock in the form of restricted stock units (RSUs) on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU converting into one share of common stock when vested.

After this grant, Johnson’s directly held common stock position was reported as 15,471 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

COYLE MICHAEL J reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Michael J. Coyle received an equity award of 2,538 restricted stock units (RSUs) tied to the company’s common stock on 2026-07-24 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, with each RSU representing a contingent right to receive one share of common stock when vested. Following this award, Coyle directly holds 17,932 shares of Haemonetics common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
Rhea-AI Summary

Bryant Diane M reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Diane M. Bryant received a grant of 2,538 restricted stock units on July 24, 2026 under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the grant date, and each unit represents a contingent right to receive one share of common stock when vested. Following this award, Bryant holds 9,664 shares of Haemonetics common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

ABERNATHY ROBERT E reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Robert E. Abernathy received a grant of 2,538 restricted stock units (RSUs) on 2026-07-24 under the Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% one year after grant, each into one share of common stock, bringing his direct holdings to 27,519 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
-
Rhea-AI Summary

Haemonetics Corp reported that Martin D. Madaus serves as a director and is now identified as a reporting person for the company’s equity securities. The insider data shows no reported transactions, with 0 shares bought or sold and no derivative positions listed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
insider
Rhea-AI Summary

Haemonetics Corporation reported that its Board of Directors elected Martin Madaus as a director, effective July 24, 2026. He is expected to join the Audit Committee and the Governance and Compliance Committee and, as a non-employee director, will receive compensation consistent with the directors’ compensation program, including an annual equity award of approximately $200,000, and will enter into the company’s standard indemnification agreement.

At the 2026 annual meeting, shareholders holding 42,051,106 of 45,445,983 entitled shares were represented, a 92.53% quorum. Shareholders elected eight directors, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm. They also approved amendments and restatements of the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending its term through 2036, and the 2007 Employee Stock Purchase Plan, also extended through 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.49%
Tags
current report

FAQ

How many HAEMONETICS (HAE) SEC filings are available on StockTitan?

StockTitan tracks 64 SEC filings for HAEMONETICS (HAE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HAEMONETICS (HAE)?

The most recent SEC filing for HAEMONETICS (HAE) was filed on November 13, 2026.